Trump Signs Psychedelic Executive Order: What It Means for Maine's Psilocybin Movement

The Executive Order: What It Does

The executive order, signed on Saturday, April 18, 2026, contains several consequential directives that collectively represent the most aggressive federal push toward psychedelic medicine since these substances were classified as Schedule I in 1970.

Key Provisions

FDA Fast-Track Review. The order instructs the FDA to expedite the review process for psychedelic drugs, particularly ibogaine and psilocybin. FDA Commissioner Dr. Marty Makary announced that three psychedelics would be added to the National Priority Voucher pilot program — a pathway designed to dramatically reduce review times for products that align with U.S. national health priorities. This is the first time the FDA has offered to fast-track any psychedelics.

$50 Million for Ibogaine Research. The federal government will dedicate $50 million specifically to research into ibogaine, a naturally occurring compound derived from the West African iboga plant. Ibogaine has shown promise in treating opioid withdrawal, post-traumatic stress disorder, and addiction, but has been difficult to study in the United States due to its Schedule I classification and known cardiotoxicity risks.

Right to Try Pathway. The order opens a pathway for ibogaine to be administered to "desperately ill patients" under the FDA's Right to Try rule, which allows eligible patients with life-threatening conditions to access investigational drugs that have completed at least one Phase I clinical trial but have not yet received FDA approval.

Reclassification Framework. Federal officials at the signing ceremony indicated that the reforms would pave the way for psychedelics to be reclassified after successful clinical trials — though the order itself does not directly reschedule any substance. Psilocybin and ibogaine remain Schedule I drugs under current federal law.

Who Was There

The Oval Office ceremony drew an unusual coalition: HHS Secretary Robert F. Kennedy Jr., who has championed psychedelic medicine as an alternative treatment for mental health conditions; FDA Commissioner Dr. Marty Makary; Dr. Mehmet Oz; podcast host Joe Rogan, who said his personal outreach to the president helped initiate the policy shift; and veterans including former Navy SEAL Marcus Luttrell and Rep. Morgan Luttrell (R-TX), both of whom credited ibogaine with transforming their mental health.

"You're going to save a lot of lives through it," Marcus Luttrell told the president. "It absolutely changed my life for the better."

Safety Concerns and Scientific Caution

The order has drawn both enthusiasm and caution from the scientific community. Ibogaine is known to cause dangerous heart rhythm disturbances, and a 2023 review of 24 studies involving 705 people found that while ibogaine appeared to reduce withdrawal symptoms and craving, toxicity to the heart and risk of death were "worrying." At least 27 people have died after taking ibogaine.

Frederick Barrett, director of the Johns Hopkins Center for Psychedelic and Consciousness Research, told CNBC: "It's been incredibly difficult to study ibogaine in the U.S. because of its known cardiotoxicity. If the executive order can pave the way for doing objective, scientific research with this compound, it would help us understand whether it is truly a better psychedelic therapy than others."

Critics have raised concerns that fast-tracking strong substances might bypass traditional safety benchmarks. The administration maintains that the urgency of the national mental health crisis — over 14 million American adults have a serious mental illness, and about 8 million are on prescription antidepressants — requires a faster pipeline for new treatments.

What's Moving in Congress: Four Major Psychedelic Bills

The executive order arrives alongside an unprecedented wave of bipartisan psychedelic legislation in Congress. Four major bills are currently pending, each addressing different aspects of psychedelic research, access, and veteran care.

S.4031 — new Therapies Centers of Excellence Act

Introduced March 9, 2026, by Sens. Ruben Gallego (D-AZ), Tim Sheehy (R-MT), and Dave McCormick (R-PA), this bill would require the Department of Veterans Affairs to establish at least five "new therapies centers of excellence" — specialized VA medical facilities dedicated to researching and providing psychedelic-assisted treatments for veterans. The bill authorizes $30 million annually and covers MDMA, psilocybin, ibogaine, ketamine, and 5-MeO-DMT for conditions including PTSD, depression, anxiety, chronic pain, and substance use disorder.

The bill was referred to the Senate Committee on Veterans' Affairs. No hearing or markup has been scheduled as of April 2026.

S.4220 — Veterans Health Administration Novel Therapeutics Preparedness Act

Introduced March 27, 2026, by Sen. Tim Sheehy (R-MT) with bipartisan co-sponsors including Sens. Ruben Gallego (D-AZ), Tammy Duckworth (D-IL), and John Boozman (R-AR), this sweeping legislation would establish a dedicated Office of Novel Therapeutics within the VA. The office would develop national clinical standards, workforce credentialing frameworks, and care delivery models for psychedelic-assisted therapy — which the bill distinguishes from traditional psychiatric medication management as requiring a specialized clinical model.

The bill also mandates a Veteran Advisory Committee, requires coordination with the FDA, DEA, and CMS, and demands annual reporting to Congress on research progress and clinical outcomes. Advocates have called it a "major step" in providing veterans with new therapeutic modalities.

H.R. 2623 — new Therapies Centers of Excellence Act (House Companion)

The House companion to S.4031, introduced by Reps. Lou Correa (D-CA) and Jack Bergman (R-MI), co-chairs of the Psychedelics Advancing Therapies (PATH) Caucus. This is the first standalone psychedelics-related legislation introduced by the PATH Caucus. Co-sponsored by Reps. Morgan Luttrell (R-TX), Ro Khanna (D-CA), and Dan Crenshaw (R-TX), the bill has been endorsed by the American Legion, Disabled American Veterans, and Iraq and Afghanistan Veterans of America.

Freedom to Heal Act (Booker-Paul)

Introduced December 2025 by Sens. Cory Booker (D-NJ) and Rand Paul (R-KY), this bipartisan proposal would expand the federal Right to Try law to grant eligible patients with life-threatening conditions legally protected access to experimental Schedule I substances — specifically targeting psilocybin, ibogaine, and MDMA — that have completed at least one Phase I clinical trial. The bill was referred to the Senate Judiciary Committee and has not advanced to a floor vote.

new Therapies Act

Originally introduced by Sens. Booker and Paul, this bill would create an administrative process by which Schedule I drugs that receive FDA new Therapy Designation can be automatically reclassified as Schedule II substances. This would remove the most significant regulatory barrier to psychedelic research and clinical use. The bill was referred to the Senate Judiciary Committee with no further action as of April 2026.

Maine's Psychedelic Legislative Effort: Where Things Stand

While federal policy is accelerating, Maine's own psychedelic reform effort reached a dramatic — and ultimately unresolved — moment in June 2025.

LD 1034: The Bill That Came Within One Vote

LD 1034, "An Act to Decriminalize Personal Possession of Therapeutic Amounts of Psilocybin for Adults," was sponsored by Rep. Grayson Lookner (D-Portland) with bipartisan support from Sens. Donna Bailey (D-York) and Craig Hickman (D-Kennebec), along with Reps. David Boyer (R-Poland), Quentin Chapman (R-Auburn), and John Eder (R-Waterboro).

The bill was straightforward: it would have exempted psilocybin from Maine's Schedule X drug classification, decriminalizing possession of one ounce or less for adults 21 and older. It would not have created a commercial market, authorized sales, or established therapeutic service programs — just removed criminal penalties for personal possession.

The bill passed the House 70-69 on June 2, 2025. It passed the Senate 17-16 on June 3. Both chambers approved it by a single vote.

Then, on June 4, during what should have been the final enactment vote, House Majority Leader Matt Moonen (D) motioned to table the bill. The House voted 74-72 against the bill on reconsideration. The Senate deadlocked 16-16 on a subsequent vote. The legislation was effectively killed.

Why It Failed

Opposition came from multiple directions. The Maine Department of Public Safety testified against the bill, with Maine Drug Enforcement Agency Commander Scott Pelletier noting that MDEA agents had seized over 4.5 pounds of psilocybin since January 2024 — mostly during investigations of mid- to high-level drug traffickers distributing psilocybin alongside fentanyl, methamphetamine, and cocaine.

The Maine Chiefs of Police Association opposed the bill. The Maine CDC took a cautious position, stating that while limited research has shown psilocybin can be beneficial, more studies are needed and the agency "disagrees with decriminalizing any possession of a substance for therapeutic purposes without the oversight of a licensed health care provider."

Governor Janet Mills (D), a former prosecutor, did not publicly weigh in on the bill, but concerns about a potential veto influenced the legislative dynamics. Several organizations had been reaching out to her office with medical literature showing psilocybin's benefits, but the governor never signaled support.

What Advocates Said

Military veterans were among the most vocal supporters of LD 1034, testifying that psilocybin had helped them manage PTSD, depression, and anxiety where conventional pharmaceuticals had failed. Aaron Parker, speaking on behalf of Decriminalize Maine, noted: "I've been watching psilocybin bills move through the Legislature and die for several years now. Most of them kind of got lost, not because there wasn't interest in proceeding with regulation but because the complexity of the bill made it come into too much conflict with existing state law."

Yeshua Adonai, a psychedelic advocate who testified in support of the bill, said after the tabling: "While this was not the outcome we hoped for, the energy on the ground remains strong."

The Commission to Study Psilocybin Services in Maine

While LD 1034 stalled, a parallel effort moved forward. The Legislature amended the bill to establish the Commission to Study Pathways for Creating a Psilocybin Services Program in Maine — a study commission tasked with examining how Maine might eventually create a regulated framework for therapeutic psilocybin use.

Commission Mandate

The commission is required to:

• Review available medical, psychological, and scientific studies on psilocybin for mental health disorders and end-of-life psychological distress
• Review efforts by other states (Oregon, Colorado) to adopt legal frameworks for therapeutic psychedelic use
• Review previously proposed Maine legislation related to psychedelic therapeutic frameworks
• Determine the steps Maine would need to take to establish and maintain a legal framework for therapeutic psilocybin use
• Develop a long-term strategic plan for creating a psilocybin services program that is safe, accessible, and affordable
• Identify populations for whom psilocybin services may be appropriate

Timeline and Next Steps

The commission must submit its report — including findings, recommendations, and suggested legislation — by November 4, 2026. The report will be presented to the Legislature's Criminal Justice and Public Safety Committee, Veterans and Legal Affairs Committee, and Health and Human Services Committee. Based on the commission's recommendations, legislation could be introduced for the 133rd Legislature in 2027.

This timeline means Maine's next serious opportunity for psilocybin reform arrives in the 2027 legislative session — potentially energized by whatever federal actions emerge from today's executive order and the pending congressional bills.

The National Psychedelic Reform Landscape in 2026

Maine's efforts are part of a broader national movement. As of early 2026:

• Oregon operates a state-regulated psilocybin therapy program under Measure 109 (2020), though local opt-outs have limited access in some counties
• Colorado voters approved regulated psychedelic access through Proposition 122 (2022), with implementation ongoing
• New Jersey enacted S2283/A3852 in January 2026, establishing a hospital-based psilocybin research program with $6 million in funding across three hospitals
• New York is considering A3845A, which would establish a psilocybin-assisted therapy pilot program for 10,000 veterans, first responders, and cluster headache patients
• Washington is considering the Natural Psychedelics Safe Access Act, which would allow personal possession, cultivation, and non-commercial sharing of psilocybin, DMT, and mescaline for adults 21 and older
• Utah is considering HB 390, authorizing a donation-funded clinical research program on psychedelic-assisted therapy for veteran PTSD
• Texas already committed $50 million for ibogaine research through legislation signed by Gov. Greg Abbott in 2025
• New Mexico is pursuing bold measures to increase legal, affordable access to psychedelic therapy

More than 25 states have enacted or introduced legislation related to psychedelic medicines since 2019, according to the Multidisciplinary Association for Psychedelic Studies (MAPS). The pace of state-level activity has accelerated dramatically in 2026.

What This Means for Maine

The convergence of federal action and state-level momentum creates a fundamentally different landscape for Maine's psychedelic reform effort than existed even six months ago.

Federal Cover for State Action

One of the most significant barriers to state-level psychedelic reform has been the stigma of Schedule I classification. Ismail Lourido Ali of the Drug Policy Alliance told CNBC that Trump's order "might encourage other states to follow suit," adding: "The stigma around Schedule I drugs is significant. It feels like this would give pretty substantial cover" for state-level action.

When the federal government is actively funding psychedelic research and fast-tracking FDA review, it becomes considerably harder for state lawmakers to argue that these substances have no therapeutic value. The political calculus shifts.

The Commission Report Timing

The Maine commission's November 2026 report deadline is strategically positioned. By the time the commission delivers its findings, the FDA will likely have acted on the executive order's directives — potentially issuing priority review vouchers, initiating ibogaine clinical trials, and signaling a path toward rescheduling. The commission will be able to incorporate these federal developments into its recommendations.

If the commission recommends a regulatory framework for therapeutic psilocybin use — modeled on Oregon or Colorado's programs — the 133rd Legislature in 2027 will be considering the proposal in a national environment that looks dramatically different from the one that existed when LD 1034 was tabled.

The Veteran Factor

Maine has one of the highest per-capita veteran populations in the United States. The bipartisan federal legislation focused on veteran access to psychedelic therapies — S.4031, S.4220, and H.R. 2623 — resonates strongly in a state where veterans were among the most compelling witnesses at LD 1034's public hearing. If the VA establishes psychedelic treatment centers of excellence, Maine veterans will have access to these therapies through the federal system regardless of state law — increasing pressure on state lawmakers to align.

What Remains Unchanged

Despite the federal executive order, psilocybin and ibogaine remain Schedule I substances under federal law. The order does not reschedule them — it directs agencies to study them and expedite review. Commercial sales, possession, and use remain illegal under federal law and under Maine state law. The executive order is a research and regulatory acceleration mechanism, not a legalization directive.

For Maine residents, the practical legal status of psilocybin has not changed as a result of today's signing. Possession of psilocybin remains a Class D crime under Maine law (17-A M.R.S. § 1102), punishable by up to 364 days in jail and a $2,000 fine.

What to Watch Next

Several developments in the coming weeks and months will shape the trajectory of psychedelic policy at both the federal and state level:

FDA Priority Voucher Issuance

FDA Commissioner Makary said the agency will issue national priority review vouchers for three psychedelics "next week" — meaning the week of April 20, 2026. Which substances receive vouchers, and for what indications, will signal the administration's priorities and the likely timeline for potential approvals.

Ibogaine Clinical Trials

The FDA is taking steps to allow the first-ever human trials of ibogaine in the United States. The design, scope, and timeline of these trials will determine whether ibogaine can overcome its cardiotoxicity concerns and achieve the safety profile required for FDA approval.

Congressional Action on VA Bills

S.4031 and S.4220 are the most likely psychedelic bills to advance in the current Congress, given their bipartisan veteran sponsorship and focus on VA infrastructure rather than broad access. If either bill reaches a committee hearing, it would represent the first congressional action on psychedelic medicine in decades.

Maine Commission Proceedings

The Commission to Study Pathways for Creating a Psilocybin Services Program in Maine will begin its work in earnest. Public hearings, expert testimony, and stakeholder input will shape the commission's November 2026 report. Advocates should monitor the commission's schedule and participate in public comment periods.

DEA Rescheduling Action

The executive order directs federal officials to explore reclassification pathways for psychedelics after successful clinical trials. Any DEA action on rescheduling — even for a single substance like ibogaine — would fundamentally alter the legal landscape for all states, including Maine.

Related Guides

Explore more about Maine's cannabis and drug policy landscape.